Biomarin Pharmaceutical Stock Forward View
| BMRN Stock | USD 56.54 0.45 0.79% |
Biomarin Stock outlook is based on your current time horizon. Although Biomarin Pharmaceutical's naive historical forecasting may sometimes provide an important future outlook for the firm, we recommend always cross-verifying it against solid analysis of Biomarin Pharmaceutical's systematic risk associated with finding meaningful patterns of Biomarin Pharmaceutical fundamentals over time.
As of today, The RSI of Biomarin Pharmaceutical's share price is at 51 suggesting that the stock is in nutural position, most likellhy at or near its resistance level. The main idea of RSI analysis is to track how fast people are buying or selling Biomarin Pharmaceutical, making its price go up or down. Momentum 51
Impartial
Oversold | Overbought |
Quarterly Earnings Growth 1.243 | EPS Estimate Next Quarter 0.9872 | EPS Estimate Current Year 3.373 | EPS Estimate Next Year 5.2146 | Wall Street Target Price 90.7391 |
Using Biomarin Pharmaceutical hype-based prediction, you can estimate the value of Biomarin Pharmaceutical from the perspective of Biomarin Pharmaceutical response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Biomarin Pharmaceutical using Biomarin Pharmaceutical's stock options and short interest. It helps to benchmark the overall future attitude of investors towards Biomarin using crowd psychology based on the activity and movement of Biomarin Pharmaceutical's stock price.
Biomarin Pharmaceutical Short Interest
An investor who is long Biomarin Pharmaceutical may also wish to track short interest. As short interest increases, investors should be becoming more worried about Biomarin Pharmaceutical and may potentially protect profits, hedge Biomarin Pharmaceutical with its derivative instruments, or be ready for some potential downside.
200 Day MA 56.6756 | Short Percent 0.0493 | Short Ratio 2.51 | Shares Short Prior Month 8.1 M | 50 Day MA 56.1656 |
Biomarin Relative Strength Index
The Naive Prediction forecasted value of Biomarin Pharmaceutical on the next trading day is expected to be 58.71 with a mean absolute deviation of 1.43 and the sum of the absolute errors of 87.22.Biomarin Pharmaceutical Hype to Price Pattern
Investor biases related to Biomarin Pharmaceutical's public news can be used to forecast risks associated with an investment in Biomarin. The trend in average sentiment can be used to explain how an investor holding Biomarin can time the market purely based on public headlines and social activities around Biomarin Pharmaceutical. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Biomarin Pharmaceutical's market sentiment to its price can help taders to make decisions based on the overall investors consensus about Biomarin Pharmaceutical.
Biomarin Pharmaceutical Implied Volatility | 0.5 |
Biomarin Pharmaceutical's implied volatility exposes the market's sentiment of Biomarin Pharmaceutical stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Biomarin Pharmaceutical's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Biomarin Pharmaceutical stock will not fluctuate a lot when Biomarin Pharmaceutical's options are near their expiration.
The Naive Prediction forecasted value of Biomarin Pharmaceutical on the next trading day is expected to be 58.71 with a mean absolute deviation of 1.43 and the sum of the absolute errors of 87.22. Biomarin Pharmaceutical after-hype prediction price | USD 56.54 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of Biomarin Pharmaceutical to cross-verify your projections. Prediction based on Rule 16 of the current Biomarin contract
Based on the Rule 16, the options market is currently suggesting that Biomarin Pharmaceutical will have an average daily up or down price movement of about 0.0313% per day over the life of the 2026-04-17 option contract. With Biomarin Pharmaceutical trading at USD 56.54, that is roughly USD 0.0177 . If you think that the market is fully incorporating Biomarin Pharmaceutical's daily price movement you should consider acquiring Biomarin Pharmaceutical options at the current volatility level of 0.5%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Open Interest Against 2026-04-17 Biomarin Option Contracts
Although open interest is a measure utilized in the options markets, it could be used to forecast Biomarin Pharmaceutical's spot prices because the number of available contracts in the market changes daily, and new contracts can be created or liquidated at will. Since open interest in Biomarin Pharmaceutical's options reflects these daily shifts, investors could use the patterns of these changes to develop long and short-term trading strategies for Biomarin Pharmaceutical stock based on available contracts left at the end of a trading day.
Please note that to derive more accurate forecasting about market movement from the current Biomarin Pharmaceutical's open interest, investors have to compare it to Biomarin Pharmaceutical's spot prices. As Ford's stock price increases, high open interest indicates that money is entering the market, and the market is strongly bullish. Conversely, if the price of Biomarin Pharmaceutical is decreasing and there is high open interest, that is a sign that the bearish trend will continue, and investors may react by taking short positions in Biomarin. So, decreasing or low open interest during a bull market indicates that investors are becoming uncertain of the depth of the bullish trend, and a reversal in sentiment will likely follow.
Biomarin Pharmaceutical Additional Predictive Modules
Most predictive techniques to examine Biomarin price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Biomarin using various technical indicators. When you analyze Biomarin charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Biomarin Pharmaceutical Cash Forecast
Forecasting financial indicators like cash flow involves analysts applying various statistical methods, techniques, and algorithms. These tools reveal hidden trends within the Biomarin Pharmaceutical's financial statements to estimate their effects on upcoming price movements.
Cash | First Reported 1999-03-31 | Previous Quarter 1.2 B | Current Value 1.3 B | Quarterly Volatility 310.3 M |
Biomarin Pharmaceutical Naive Prediction Price Forecast For the 1st of February
Given 90 days horizon, the Naive Prediction forecasted value of Biomarin Pharmaceutical on the next trading day is expected to be 58.71 with a mean absolute deviation of 1.43, mean absolute percentage error of 3.33, and the sum of the absolute errors of 87.22.Please note that although there have been many attempts to predict Biomarin Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Biomarin Pharmaceutical's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Biomarin Pharmaceutical Stock Forecast Pattern
| Backtest Biomarin Pharmaceutical | Biomarin Pharmaceutical Price Prediction | Buy or Sell Advice |
Biomarin Pharmaceutical Forecasted Value
In the context of forecasting Biomarin Pharmaceutical's Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Biomarin Pharmaceutical's downside and upside margins for the forecasting period are 55.88 and 61.53, respectively. We have considered Biomarin Pharmaceutical's daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Biomarin Pharmaceutical stock data series using in forecasting. Note that when a statistical model is used to represent Biomarin Pharmaceutical stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 119.3141 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 1.4298 |
| MAPE | Mean absolute percentage error | 0.0258 |
| SAE | Sum of the absolute errors | 87.216 |
Predictive Modules for Biomarin Pharmaceutical
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Biomarin Pharmaceutical. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Biomarin Pharmaceutical After-Hype Price Density Analysis
As far as predicting the price of Biomarin Pharmaceutical at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Biomarin Pharmaceutical or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Biomarin Pharmaceutical, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Biomarin Pharmaceutical Estimiated After-Hype Price Volatility
In the context of predicting Biomarin Pharmaceutical's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Biomarin Pharmaceutical's historical news coverage. Biomarin Pharmaceutical's after-hype downside and upside margins for the prediction period are 53.69 and 59.39, respectively. We have considered Biomarin Pharmaceutical's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Biomarin Pharmaceutical is very steady at this time. Analysis and calculation of next after-hype price of Biomarin Pharmaceutical is based on 3 months time horizon.
Biomarin Pharmaceutical Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Biomarin Pharmaceutical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biomarin Pharmaceutical backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Biomarin Pharmaceutical, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.15 | 2.82 | 0.07 | 0.02 | 9 Events / Month | 6 Events / Month | In about 9 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
56.54 | 56.54 | 0.00 |
|
Biomarin Pharmaceutical Hype Timeline
Biomarin Pharmaceutical is currently traded for 56.54. The entity has historical hype elasticity of 0.07, and average elasticity to hype of competition of -0.02. Biomarin is projected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is projected to be very small, whereas the daily expected return is currently at 0.15%. %. The volatility of related hype on Biomarin Pharmaceutical is about 1843.14%, with the expected price after the next announcement by competition of 56.52. About 98.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.79. Some equities with similar Price to Book (P/B) outperform the market in the long run. Biomarin Pharmaceutical has Price/Earnings To Growth (PEG) ratio of 0.44. The entity had not issued any dividends in recent years. Given the investment horizon of 90 days the next projected press release will be in about 9 days. Check out Historical Fundamental Analysis of Biomarin Pharmaceutical to cross-verify your projections.Biomarin Pharmaceutical Related Hype Analysis
Having access to credible news sources related to Biomarin Pharmaceutical's direct competition is more important than ever and may enhance your ability to predict Biomarin Pharmaceutical's future price movements. Getting to know how Biomarin Pharmaceutical's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Biomarin Pharmaceutical may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| EXEL | Exelixis | 0.95 | 10 per month | 1.75 | 0.01 | 4.06 | (2.93) | 11.45 | |
| MRNA | Moderna | 1.72 | 7 per month | 4.03 | 0.16 | 10.85 | (7.01) | 23.11 | |
| RVMD | Revolution Medicines | 12.18 | 8 per month | 2.99 | 0.18 | 4.56 | (2.52) | 45.50 | |
| TECH | Bio Techne Corp | 0.06 | 11 per month | 1.77 | (0.01) | 3.72 | (2.93) | 9.58 | |
| HALO | Halozyme Therapeutics | (6.01) | 15 per month | 1.69 | 0.05 | 3.44 | (2.83) | 9.83 | |
| MDGL | Madrigal Pharmaceuticals | (7.77) | 11 per month | 2.07 | 0.06 | 7.29 | (3.26) | 16.78 | |
| RNA | Avidity Biosciences | 0.04 | 12 per month | 0.00 | 0.04 | 0.38 | (0.34) | 1.75 | |
| BBIO | BridgeBio Pharma | (1.38) | 11 per month | 1.75 | 0.13 | 4.23 | (2.55) | 12.16 | |
| ALGN | Align Technology | (0.10) | 8 per month | 1.21 | 0.13 | 4.53 | (2.32) | 10.81 | |
| QGEN | Qiagen NV | (1.22) | 10 per month | 1.17 | 0.08 | 2.86 | (2.50) | 19.10 |
Other Forecasting Options for Biomarin Pharmaceutical
For every potential investor in Biomarin, whether a beginner or expert, Biomarin Pharmaceutical's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Biomarin Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Biomarin. Basic forecasting techniques help filter out the noise by identifying Biomarin Pharmaceutical's price trends.Biomarin Pharmaceutical Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Biomarin Pharmaceutical stock to make a market-neutral strategy. Peer analysis of Biomarin Pharmaceutical could also be used in its relative valuation, which is a method of valuing Biomarin Pharmaceutical by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Biomarin Pharmaceutical Market Strength Events
Market strength indicators help investors to evaluate how Biomarin Pharmaceutical stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Biomarin Pharmaceutical shares will generate the highest return on investment. By undertsting and applying Biomarin Pharmaceutical stock market strength indicators, traders can identify Biomarin Pharmaceutical entry and exit signals to maximize returns.
Biomarin Pharmaceutical Risk Indicators
The analysis of Biomarin Pharmaceutical's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Biomarin Pharmaceutical's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting biomarin stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 1.63 | |||
| Semi Deviation | 1.58 | |||
| Standard Deviation | 2.8 | |||
| Variance | 7.84 | |||
| Downside Variance | 3.05 | |||
| Semi Variance | 2.51 | |||
| Expected Short fall | (1.87) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Biomarin Pharmaceutical
The number of cover stories for Biomarin Pharmaceutical depends on current market conditions and Biomarin Pharmaceutical's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Biomarin Pharmaceutical is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Biomarin Pharmaceutical's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Check out Historical Fundamental Analysis of Biomarin Pharmaceutical to cross-verify your projections. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Will Biotechnology sector continue expanding? Could Biomarin diversify its offerings? Factors like these will boost the valuation of Biomarin Pharmaceutical. Projected growth potential of Biomarin fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Biomarin Pharmaceutical data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.243 | Earnings Share 2.69 | Revenue Per Share | Quarterly Revenue Growth 0.041 | Return On Assets |
Understanding Biomarin Pharmaceutical requires distinguishing between market price and book value, where the latter reflects Biomarin's accounting equity. The concept of intrinsic value—what Biomarin Pharmaceutical's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Biomarin Pharmaceutical's price substantially above or below its fundamental value.
It's important to distinguish between Biomarin Pharmaceutical's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biomarin Pharmaceutical should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Biomarin Pharmaceutical's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.